Atlas Trials

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Clinical trial NCT03813784 · COMPLETED

Trial details

NCT number
NCT03813784
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Gastric CancerGastroEsophageal Cancer
Start date
2019-03-07
Primary completion
2023-06-07
Enrollment
885

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.